Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE138267

Dataset summary for GSE138267

Datast information	Dataset	GSE138267
	PMID	33521652
	Raw data ID/link	PRJNA575243
	Organism	Homo sapiens
	Source	CDX
	Tissue	Tumor tissue
	Cancer type level1	Lung cancer
	Cancer type level2	Small cell lung cancer (SCLC)
	Regimen	NA
	Drug type	Chemotherapy
	Sample size	resistant 4, sensitive 4
	Cell number	61001
	Extract protocol	10x genomics
	Data processing	CellRanger 2.0.0
	Public date	Public on Feb 12, 2020
	Description	This dataset has 8 PDX.

Top

Drug summary for GSE138267

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"" is not included in the drug list.

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types

Umap of conditions

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
IFI27	ENSG00000275214	3.17778	0.00e+00	0.00e+00	0.443	0.316	Malignant cells	NA
AVP	ENSG00000101200	3.01296	0.00e+00	0.00e+00	0.519	0.091	Malignant cells	NA
AQP3	ENSG00000165272	2.15144	0.00e+00	0.00e+00	0.373	0.024	Malignant cells	NA
B2M	ENSG00000273686	1.72138	0.00e+00	0.00e+00	0.955	0.904	Malignant cells	NA
DEFB1	ENSG00000164825	1.68136	0.00e+00	0.00e+00	0.437	0.049	Malignant cells	NA
GRP	ENSG00000134443	1.48843	5.48e-10	1.53e-05	0.733	0.906	Malignant cells	NA
ANXA2	ENSG00000182718	1.47886	0.00e+00	0.00e+00	0.696	0.765	Malignant cells	NA
SCPEP1	ENSG00000121064	1.43553	0.00e+00	0.00e+00	0.685	0.652	Malignant cells	NA
RPS17	ENSG00000278229	1.4085	0.00e+00	0.00e+00	0.254	0.165	Malignant cells	NA
MYO6	ENSG00000196586	1.39916	0.00e+00	0.00e+00	0.369	0.165	Malignant cells	NA
IFI6	ENSG00000126709	1.34918	0.00e+00	0.00e+00	0.605	0.101	Malignant cells	NA
ID1	ENSG00000125968	1.29187	0.00e+00	0.00e+00	0.726	0.578	Malignant cells	NA
S100A14	ENSG00000189334	1.24143	0.00e+00	0.00e+00	0.453	0.043	Malignant cells	NA
HIST1H1C	NA	1.23655	0.00e+00	0.00e+00	0.464	0.412	Malignant cells	NA
PLIN2	ENSG00000147872	1.21124	0.00e+00	0.00e+00	0.515	0.631	Malignant cells	NA
CA9	ENSG00000107159	1.20665	0.00e+00	0.00e+00	0.416	0.077	Malignant cells	NA
TCF4	ENSG00000196628	1.18131	0.00e+00	0.00e+00	0.489	0.138	Malignant cells	NA
PHLDA2	ENSG00000274538	1.16791	0.00e+00	0.00e+00	0.411	0.117	Malignant cells	NA
LINC00930	ENSG00000258647	1.16271	0.00e+00	0.00e+00	0.303	0.003	Malignant cells	NA
FABP5	ENSG00000164687	1.12566	0.00e+00	0.00e+00	0.722	0.865	Malignant cells	NA
IGF2	ENSG00000167244	1.12456	0.00e+00	0.00e+00	0.318	0.011	Malignant cells	NA
NEB	ENSG00000183091	1.11964	0.00e+00	0.00e+00	0.371	0.035	Malignant cells	NA
CAMK2B	ENSG00000058404	1.11639	0.00e+00	0.00e+00	0.5	0.139	Malignant cells	NA
CPE	ENSG00000109472	1.09628	0.00e+00	0.00e+00	0.961	0.754	Malignant cells	NA
NDUFA4L2	ENSG00000185633	1.08922	0.00e+00	0.00e+00	0.472	0.463	Malignant cells	NA
S100A16	ENSG00000188643	1.08384	0.00e+00	0.00e+00	0.328	0.038	Malignant cells	NA
C21orf59	NA	1.07945	0.00e+00	0.00e+00	0.733	0.597	Malignant cells	NA
SEPT11	NA	1.04707	0.00e+00	0.00e+00	0.582	0.554	Malignant cells	NA
TOP2A	ENSG00000131747	1.03919	0.00e+00	0.00e+00	0.477	0.45	Malignant cells	NA
ID3	ENSG00000283060	0.988659	0.00e+00	0.00e+00	0.653	0.456	Malignant cells	NA
ALDOA	ENSG00000149925	0.987787	0.00e+00	0.00e+00	0.989	0.913	Malignant cells	NA
RPS4Y1	ENSG00000129824	0.986063	0.00e+00	0.00e+00	0.389	0.072	Malignant cells	NA
TFAP2B	ENSG00000008196	0.98248	0.00e+00	0.00e+00	0.375	0.005	Malignant cells	NA
HAPLN1	ENSG00000145681	0.978317	0.00e+00	0.00e+00	0.32	0	Malignant cells	NA
KCNMA1	ENSG00000156113	0.97658	0.00e+00	0.00e+00	0.507	0.112	Malignant cells	NA
CXCL17	ENSG00000189377	0.964438	0.00e+00	0.00e+00	0.314	0.009	Malignant cells	NA
NHLH1	ENSG00000171786	0.957016	0.00e+00	0.00e+00	0.294	0.003	Malignant cells	NA
TMSB10	ENSG00000034510	0.947188	0.00e+00	0.00e+00	1	0.991	Malignant cells	NA
TUBB4B	ENSG00000188229	0.938527	0.00e+00	0.00e+00	0.986	0.924	Malignant cells	NA
C8orf22	NA	0.937854	0.00e+00	0.00e+00	0.251	0	Malignant cells	NA
LMO2	ENSG00000135363	0.937172	0.00e+00	0.00e+00	0.435	0.099	Malignant cells	NA
NFIA	ENSG00000162599	0.936482	0.00e+00	0.00e+00	0.419	0.053	Malignant cells	NA
HLA-A	ENSG00000227715	0.932829	0.00e+00	0.00e+00	0.848	0.852	Malignant cells	NA
ITM2C	ENSG00000135916	0.930251	0.00e+00	0.00e+00	0.636	0.165	Malignant cells	NA
MAFB	ENSG00000204103	0.929969	0.00e+00	0.00e+00	0.506	0.149	Malignant cells	NA
EFHD2	ENSG00000142634	0.925409	0.00e+00	0.00e+00	0.588	0.242	Malignant cells	NA
HMGB2	ENSG00000164104	0.9229	0.00e+00	0.00e+00	0.958	0.9	Malignant cells	NA
NUSAP1	ENSG00000137804	0.914013	0.00e+00	0.00e+00	0.561	0.553	Malignant cells	NA
LHX1	ENSG00000274577	0.907415	0.00e+00	0.00e+00	0.314	0.005	Malignant cells	NA
PGF	ENSG00000119630	0.906466	0.00e+00	0.00e+00	0.394	0.077	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	3.30e-15	1.60e-14	1319	781	101	23467	Malignant cells	AKAP1,ANXA2,ATG12,AURKA,CDK4,CDKN1B,TP53,CIAPIN1,DLK1,GSTP1,SLC2A1,HIF1A,HMGA1,HOXB3,ID1,IDH2,IFI27,ISG15,PKM,RPS6,SOX2,SOX4,STMN1,TPD52,TYMS,SLC25A5,TFAP2A,ARID1A,ATG4B,BNIP2,BRD4,BRD7,CCNB1,CDK1,CCNG1,ALCAM,CDC27,CDKN2A,CRBN,CREB1,CXCR4,DCK,DNMT3A,DHFR,EHF,ERCC1,EZR,FIS1,FTL,GAPDH,GAS6,NR3C1,HAX1,HDAC1,HMGB2,HMGN5,HNRNPU,HSPB1,EIF4A3,TCF4,KDM5B,KLF4,LDHA,LRRFIP1,MDM4,MYBL2,NQO1,NUCKS1,TP73,PABPC1,AGPAT2,PTPN1,HRAS,REV1,RRM2,RSF1,SDHB,SMC4,SOCS3,SRSF2,STAT3,SUZ12,TMEM54,TOP1,TUSC3,UBE2C,USP14,USP22,UCP2,WLS,YBX1,ENO1,GNAS,CALR,EIF4EBP1,BRD2,NKX2-1,G3BP1,PMVK,EBP,CERS6
Drug Inactivation by Structure Modification	1.90e-01	4.00e-01	1319	27	3	23467	Malignant cells	GSTP1,DCK,CMPK1
Aberration of the Drug's Therapeutic Target	2.40e-01	4.00e-01	1319	90	7	23467	Malignant cells	CDK4,TP53,IDH2,CDKN2A,CRBN,DHFR,TOP2A
Irregularity in Drug Uptake and Drug Efflux	3.50e-01	4.30e-01	1319	37	3	23467	Malignant cells	SLC3A2,SLC2A1,TAP1
Epigenetic Alteration of DNA, RNA or Protein	9.90e-01	9.90e-01	1319	455	16	23467	Malignant cells	TP53,H2AFY,IDH2,EIF4G2,LMNA,TYMS,PMAIP1,CDKN2A,CXCR4,DNMT3A,GAPDH,SMC4,TIMP1,MALAT1,GDI2,MT-CO2

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__GCM1_SPDEF_RTGNKGGCGGAWG_CAP_repr	3.63	0.0606	GCM1; SPDEF (directAnnotation).	Malignant cells
	transfac_pro__M01219	3.55	0.06	SP1 (directAnnotation). SP3 (inferredBy_Orthology).	Malignant cells
	transfac_pro__M07397	3.53	0.0598	ZNF148 (directAnnotation).	Malignant cells
	metacluster_131.7	3.43	0.059	EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; EGR3; EGR3; EGR3; EGR3; EGR4; EGR4; WT1 (directAnnotation). EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; WT1; ZBTB43; ZBTB43; ZBTB43; ZBTB43; ZBTB5; ZBTB5; ZBTB5; ZBTB5; ZBTB7A; ZBTB7A; ZBTB7A; ZBTB7A; ZNF367; ZNF367; ZNF367; ZNF367; ZNF740; ZNF740; ZNF740; ZNF740 (inferredBy_Orthology).	Malignant cells
	metacluster_131.4	3.39	0.0587	EGR2; EGR2; ZFHX2; ZNF141 (directAnnotation).	Malignant cells
	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	3.37	0.0585	GMEB1 (directAnnotation).	Malignant cells
	taipale_cyt_meth__ZNF281_NCCCCTCCCCCN_eDBD_meth	3.35	0.0584	ZNF281 (directAnnotation).	Malignant cells
	metacluster_15.2	3.33	0.0583	E2F1; E2F1; E2F1; E2F1; E2F1; E2F3; E2F4; E2F4; E2F4; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F7; TFDP1; TFDP2; ZNF566; ZNF566; ZNF574 (directAnnotation). E2F3; E2F3; E2F4 (inferredBy_Orthology).	Malignant cells
	metacluster_7.13	3.32	0.0582	ZFX (directAnnotation).	Malignant cells
	metacluster_3.11	3.32	0.0582	SP1; SP1; SP2; SP3; SP3; SP4 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	4.28	0.0499	ETS2 (directAnnotation).	Malignant cells
	jaspar__MA1483.2	3.94	0.0476	ELF2 (directAnnotation).	Malignant cells
	transfac_pro__M05481	3.92	0.0474	ZNF202 (directAnnotation).	Malignant cells
	transfac_pro__M05846	3.63	0.0454	ZNF689 (directAnnotation).	Malignant cells
	transfac_pro__M06827	3.58	0.045	ZBTB11 (directAnnotation).	Malignant cells
	taipale_tf_pairs__MYBL1_ELF1_NMCCGGAACCGTTR_CAP_repr	3.57	0.0449	ELF1; MYBL1 (directAnnotation).	Malignant cells
	transfac_pro__M05522	3.52	0.0446	ZNF341 (directAnnotation).	Malignant cells
	swissregulon__hs__ETV6	3.49	0.0444	ETV6 (directAnnotation).	Malignant cells
	transfac_pro__M05298	3.42	0.0439	OVOL3 (directAnnotation).	Malignant cells
	metacluster_33.5	3.35	0.0434	MTF1 (inferredBy_Orthology).	Malignant cells

Page: 1 2 3 4

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
ETS2	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	up	Malignant cells	NA
ELF2	jaspar__MA1483.2	up	Malignant cells	NA
ELF2	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	up	Malignant cells	NA
TFAP2A	tfdimers__MD00275	up	Malignant cells	NA
HES6	jaspar__MA1493.1	up	Malignant cells	NA
CHD2	metacluster_172.6	up	Malignant cells	NA
ZNF281	taipale_cyt_meth__ZNF281_NCCCCTCCCCCN_eDBD_meth	up	Malignant cells	NA
SP3	metacluster_3.11	up	Malignant cells	NA
SP3	metacluster_3.7	up	Malignant cells	NA
NR3C1	metacluster_141.5	up	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."